Showing results (41-50 of 78) with videos related to
Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|July 9, 2021
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saiag, Caroline Robert, Jean-Jacques Grob, et al.Prostate Cancer and Prostatic Diseases|October 26, 2023
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancerRobert Hugh Jones, Karim Fizazi, Nicholas D James, et al.JCO Precision Oncology|November 10, 2022
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National CohortManon Girod, Stéphane Dalle, Laurent Mortier, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patientsNadege Bercovici, Nacilla Haicheur, Severine Massicard, et al.International Journal of Clinical Oncology|March 28, 2020
Implementation of a molecular tumor board at a regional level to improve access to targeted therapyHéloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)Stéphane Culine, Alain Lortholary, Jean-Jacques Voigt, et al.Melanoma Research|November 11, 2024
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohortCamille Macaire, Wendy Lefevre, Sophie Dalac, et al.Targeted Oncology|November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsJean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.Cancers|July 3, 2020
Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCeleste Lebbé, Caroline Dutriaux, Thierry Lesimple, et al.Targeted Oncology|November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation TrialCéleste Lebbé, Antoine Italiano, Nadine Houédé, et al.Pageof 8